Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aspire Biopharma Holdings, Inc.
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
April 16, 2026
Aspire Biopharma’s Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
April 15, 2026
Aspire Biopharma’s Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
March 19, 2026
Aspire Biopharma’s Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
March 17, 2026
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
March 3, 2026
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
February 13, 2026
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
February 12, 2026
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
February 11, 2026
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 10, 2026
Aspire Biopharma’s Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
February 10, 2026
←
Previous Page
1
2